应用诺和灵R治疗磺脲类药物继发失效2型糖尿病的临床观察

Efficacy of Novolin R on type 2 diabetes mellitus patients with secondary failure to sulfonylurea

目的 :观察磺脲类药物继发失效的 2型糖尿病应用诺和灵 R的疗效。方法 :停用口服降糖药后 ,将 30例磺脲类药物继发失效的 2型糖尿病应用诺和灵 R治疗 4周 ,测定治疗前后空服血糖(FBG)、餐后 2 h血糖 (2 h BG)及糖化血红蛋白 (Hb A1 c)水平 ,以观察疗效。结果 :空腹血糖 (FBG)及餐后2 h血糖 (2 h BG)明显下降 ,分别从治疗前 14 .73± 1.14 mmol/ L和 16 .94± 0 .6 mmol/ L下降到治疗后5 .96± 0 .33mmol/ L和 10 .6 8± 0 .32 mmol/ L :糖化血红蛋白 (Hb A1 c)亦明显下降 ,从治疗 (9.34± 0 .18(% )下降到治疗后 7.2 8± 0 .35 (% )。结论 :诺和灵

Objective:Studing the efficacy of the Novolin R in the treatment of type 2 diabetes mellitus patients with secondary failure to sulfonylurea. Methods:Stop oral hypoglycaemic agents,30 cases type 2 diabetes mellitus patients with secondary failure to sulfonylurea were treated with Novolin R for 4 weeks to evaluate the therapeutic effect.The level of fasting and 2 hour postprandial,as well as HbA 1c were evaluated before and four weeks after treatment.Results:The level of fasting and 2 hour postprandial blood glucose were 14.73±1.14mmol/L,16.94±0.6mmol/L at the begining of the study and decreased 5.96±0.33mmol/L,10.68±0.32mmol/L at the end of 4 weeks respectively,HbA 1c cdecreased markedly from 9.34±0.18(%) to 7.28±0.35(%)before and four weeks after treatment.Conclusion:Novolin R is an effective therapeutic method in the treatment of type 2 diabetes mellitus patients with secondary failure to sulfonylurea.